Trial
NCT02657369
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eisai Inc.
Collaborators
—
Condition
Thyroid Carcinoma, Anaplastic
Intervention
Lenvatinib 24 mg
Why stopped
Overall response rate was 3% (only 1 out of 33 participants had confirmed PR).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-15